People · Operator
Named in public records as an officer, director or promoter · active 2015–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Envisia Therapeutics, Inc. | — | Biotechnology | Series A | $14.7M | $365.8M | 2015 |
Ben Yerxa at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ben Yerxa on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Bloch | 1 | 15 |
| Ed Mathers | 1 | 11 |
| Adrienne Graves | 1 | 6 |
| Seth Rudnick | 1 | 5 |
| Gary Phillips | 1 | 4 |
| Eric Linsley | 1 | 4 |
| Neal Fowler | 1 | 4 |
| William Yelle | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.